WO2017193186A1 - Composições cosméticas para reparação cutânea - Google Patents
Composições cosméticas para reparação cutânea Download PDFInfo
- Publication number
- WO2017193186A1 WO2017193186A1 PCT/BR2016/050362 BR2016050362W WO2017193186A1 WO 2017193186 A1 WO2017193186 A1 WO 2017193186A1 BR 2016050362 W BR2016050362 W BR 2016050362W WO 2017193186 A1 WO2017193186 A1 WO 2017193186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- mmp
- treatment
- regeneration
- repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to skin-repairing cosmetic compositions comprising at least one oil selected from Bertholletia excelsa or Fevillea trilobata and cosmetically acceptable excipients, as well as their use and methods for skin regeneration and healing, providing anti-aging treatment, treatment. of sensitized skin after aesthetic procedures and dry skin, by modulating cellular processes involved in the mechanisms of skin regeneration and healing. It also contemplates an in vitro method for skin repair evaluation.
- the skin has the enormous ability to constantly regenerate. On average, every 28 days a cell walks from the dermo-epidermal junction to the horn extract and then detaches like a dead cell.
- This ability to regenerate is substantially compromised by several environmental and physiological factors, such as loss of hydration, action of external agents such as sun, pollutants, air humidity, disease, smoking, direct damage to the surface of the corneal layer (such as burn, abrasions, rupture, etc.).
- Impairment of skin regeneration capacity can also be asserted by aging, as the rate of cell death and regeneration cycle decreases.
- Skin repair takes two forms: regeneration and healing. These are processes classified as inflammatory in nature. When an inflammatory process, which is always a defense mechanism against an offending agent, begins, the triggering mechanisms of healing and regeneration also begin.
- Regeneration can be defined as the process by which cells that have died due to aggression are replaced by cells in the parenchyma of the same organ. And healing occurs through a highly organized and dynamic multi-stage complex process involving several important cell types in restoring and maintaining tissue integrity.
- the process of skin repair can occur even in the absence of visible lesions to the naked eye, for example by micro-lesions occurring after environmental exposure (UV, weather, dryness, aging). It includes the steps of initial signaling (which can be verified by FGF-2 dosage), inflammation (which can be verified by inflammatory cytokine dosage (IL-1 B, IL-6, IL-8JL-10, IL-12 p70), cell migration and proliferation (which can be verified by cell proliferation assays) and remodeling and resolution (which can be verified by MMP-13 dosage or collagenase and elastase enzyme activity).
- initial signaling which can be verified by FGF-2 dosage
- inflammation which can be verified by inflammatory cytokine dosage (IL-1 B, IL-6, IL-8JL-10, IL-12 p70)
- cell migration and proliferation which can be verified by cell proliferation assays
- remodeling and resolution which can be verified by MMP-13 dosage or collagenase and elastase enzyme activity.
- the present invention relates to cosmetic skin repair compositions comprising at least one oil selected from Bertholletia excelsa (known as Brazil nuts) or Fevillea trilobata (known as nhandiroba) and cosmetically acceptable excipients.
- Cosmetic skin repair compositions according to the present invention may be available in different cosmetic forms, including without limitation emulsions, gels, powders, sticks, among others, including cosmetically appropriate vehicles / excipients known in the art. for the chosen cosmetic form.
- compositions provide anti-aging treatment including reduction of wrinkles and promotion of skin's regenerative capacity, promotion of firmness and elasticity, particularly reduced with age, as well as treatment of post-sensitized skin.
- -aesthetic procedures for example hair removal, laser, peeling or dermabrasion, treatment of dry skin (oiliness control).
- compositions according to the present invention are suitable for both facial and body use.
- compositions according to the present invention are proven to be efficient in modulating cellular processes involved in skin repair, particularly in the regeneration and healing mechanisms of the skin, including FGF-2 which signals the onset of the healing process, inflammatory cytokines.
- FGF-2 which signals the onset of the healing process
- IL-1 B, IL-6, IL-8, IL-10, IL-12 cell migration and proliferation associated with skin barrier construction and elastase activity (MMP-12) degrading elastin, MMP-13, glycosaminoglycans and elastin.
- MMP-12 elastase activity
- the present invention also contemplates the use of cosmetic skin repair compositions according to the present invention and methods related to the cosmetic treatment of skin regeneration and healing, particularly by modulating cellular processes involved in skin repair associated with skin regeneration and healing mechanisms, including FGF , IL-1B, IL-6, IL-8, IL-10, IL-12, cell migration and proliferation, elastase activities, MMP-13, glycosaminoglycans and elastin.
- the present invention also contemplates an in vitro method for evaluating skin repair, suitable for the study of various actives, which comprises the following steps:
- Step 1 Initial signaling: FGF-2 growth factor quantification by flow cytometry technique
- Step 2 Inflammation: Quantification of inflammatory cytokines (IL-1 B, IL-6, IL-8, IL-10, IL-12 p70) by flow cytometry technique;
- tissue regeneration (healing) can be divided into four sequential steps that have as their ultimate goal the restoration of cellular architecture and function. Thus, to characterize this process, some key events of each of these steps were defined for their respective in vitro measurement.
- Step 1 Initial signaling: FGF2 growth factor quantification by flow cytometry technique
- Step 2 Inflammation: Quantification of inflammatory cytokines (IL-1 B, IL-6, IL-8JL-10, IL-12 p70) by flow cytometry technique;
- FGFs comprise a family of 22 polypeptides that regulate proliferation, differentiation, migration and survival of different cell types. Their functions are performed by activating four transmembrane receptor tyrosine kinases called FGFR1 -4.
- FGF basic FGF
- Cytokines are small secreted proteins that affect the behavior of immune cells as well as other cells. These include interleukins, lymphokines and some related signaling molecules such as TNF-alpha (tumor necrosis factor-alpha) and interferons. Chemokines (or chemotactic cytokines) comprise a subset of cytokines that stimulate leukocyte chemotaxis and extravasation to sites of injury.
- Proinflammatory cytokines including IL-1 alpha and IL-1 beta,
- IL-6 and TNF-alpha play an important role in lesion repair because they induce biological responses at the lesion site, including stimulation of keratinocyte and fibroblast proliferation, ECM protein synthesis and degradation, fibroblast chemotaxis, and regulation of the immune response. .
- the Production of these cytokines should occur at low levels and should be combined with production of anti-inflammatory cytokines such as IL-10, the major cytokine responsible for resolving the inflammatory process at the site of injury. Corroborating this information, all increases observed for proinflammatory cytokines in this study represented low but significant levels and were combined with the observation of increased antiinflammatory cytokine IL-10.
- MMP-1 Colaaenase
- MMP-2 Collagen IV Elastase
- MMP-12 Elastase
- Quantification of MMP-13 Colaaenase III
- the proteins that make up the extracellular matrix include collagen, adhesive glycoproteins (fibrulin, fibrillin, elastin), proteoglycans, among others. Through structural domains, these proteins promote biological activities, modulate the activity of growth factors and cytokines and comprise recognition sites for interaction with specific cell membrane receptors. These proteins form a structural scaffold in all tissues, interacting with each other in building large structural networks. The synthesis, deposition and remodeling of these proteins are essential for restoration of damaged tissues during healing.
- Collagen represents the most abundant protein in our body, with literature describing at least 19 different types of collagen. In the skin, collagen is predominantly type I and III occurring in a 4: 1 ratio and is responsible for maintaining skin structure, strength and integrity. Type IV collagen is a component of the endothelial and epidermal basement membranes.
- collagen III predominates, which is replaced by collagen I in the later stages.
- MMP-1 1 and MMP-13 are released by endothelial cells and fibroblasts, which allows these cells to migrate, while macrophage and neutrophil proteases remove degraded matrix components promoting remodeling of repaired tissue.
- Bertholletia excelsa and / or Fevillea trilobata oils have biological activity related to skin regeneration / repair (Table 1), similar to that observed for some patterns like madecassoside. Comparatively, Bertholletia excelsa oil still had a higher potential for modulating this activity than Fevillea trilobata oil.
- these oils may be associated with products indicated for sensitized skin after aesthetic procedures, damaged skin (with microlesions), dry skin or even anti-aging, since there is a gradual reduction of the regenerative capacity of the skin with the advancement of skin. age.
- compositions according to the present invention are proven (in vitro) efficient in modulating cellular processes involved in skin repair, particularly in skin regeneration and healing mechanisms, including FGF-2, IL inflammatory cytokines. -1 B, IL-6, IL-8, IL-10, IL-12, cell migration and proliferation and elastase activity (MMP-12), MMP-13, glycosaminoglycans and elastin, providing anti-aging effect, including reduction of wrinkles and promotion of skin regenerative capacity, firmness and elasticity, as well as treatment of sensitized skin after aesthetic procedures, and dry or damaged skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/301,159 US20190282492A1 (en) | 2016-05-12 | 2016-12-29 | Cosmetic compositions for skin reparation |
| MX2018013860A MX2018013860A (es) | 2016-05-12 | 2016-12-29 | Composiciones cosmeticas para reparacion cutanea. |
| BR112018073287A BR112018073287A2 (pt) | 2016-05-12 | 2016-12-29 | composições cosméticas para reparação cutânea |
| EP16901174.9A EP3456313A4 (en) | 2016-05-12 | 2016-12-29 | COSMETIC COMPOSITIONS FOR SKIN REPAIR |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335397P | 2016-05-12 | 2016-05-12 | |
| US62/335,397 | 2016-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017193186A1 true WO2017193186A1 (pt) | 2017-11-16 |
Family
ID=60266045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2016/050362 Ceased WO2017193186A1 (pt) | 2016-05-12 | 2016-12-29 | Composições cosméticas para reparação cutânea |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190282492A1 (pt) |
| EP (1) | EP3456313A4 (pt) |
| AR (1) | AR107263A1 (pt) |
| BR (1) | BR112018073287A2 (pt) |
| CL (1) | CL2018003212A1 (pt) |
| MX (1) | MX2018013860A (pt) |
| WO (1) | WO2017193186A1 (pt) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023774A1 (pt) * | 2017-07-31 | 2019-02-07 | Natura Cosméticos S.A. | Complexo cosmético para hidratação bioativa, composição cosmética, uso e método |
| WO2020206513A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Uso do óleo de fevillea trilobata |
| WO2020206515A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Composição cosmética tópica e usos da mesma |
| WO2020206514A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Complexo cosmético e usos do mesmo |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV15615B (lv) * | 2021-11-30 | 2023-02-20 | Rīgas Stradiņa Universitāte | Krēms roku ādas epidermālās lipīda barjeras aizsardzībai un nostiprināšanai, gadījumos, kad āda tiek pakļauta biežai dezinfekcijas līdzekļu iedarbībai |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0853360A (ja) * | 1994-06-10 | 1996-02-27 | Suntory Ltd | ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品 |
| US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
| US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
| US6596287B2 (en) * | 1997-05-27 | 2003-07-22 | Semibiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US20120071263A1 (en) * | 2008-05-16 | 2012-03-22 | Taylor Made Golf Company, Inc. | Golf club |
| US20160058689A1 (en) * | 2014-08-28 | 2016-03-03 | Natura Cosméticos S.A. | Compositions for Cosmetic Formulation Comprising A Mixture Selected From Murumuru Butter, Ucuúba Butter, Brazilian-Nut Oil, Passion Fruit Oil, Cupuassu Butter, Assaí Oil and / or Nhandiroba Oil and / or Esters Therefor, As Well As The Use Of A Mixture for Preparation Of A Cosmetic Product |
-
2016
- 2016-12-29 AR ARP160104076A patent/AR107263A1/es unknown
- 2016-12-29 EP EP16901174.9A patent/EP3456313A4/en not_active Withdrawn
- 2016-12-29 BR BR112018073287A patent/BR112018073287A2/pt not_active Application Discontinuation
- 2016-12-29 MX MX2018013860A patent/MX2018013860A/es unknown
- 2016-12-29 WO PCT/BR2016/050362 patent/WO2017193186A1/pt not_active Ceased
- 2016-12-29 US US16/301,159 patent/US20190282492A1/en not_active Abandoned
-
2018
- 2018-11-12 CL CL2018003212A patent/CL2018003212A1/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0853360A (ja) * | 1994-06-10 | 1996-02-27 | Suntory Ltd | ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品 |
| US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
| US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
| US6596287B2 (en) * | 1997-05-27 | 2003-07-22 | Semibiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US20120071263A1 (en) * | 2008-05-16 | 2012-03-22 | Taylor Made Golf Company, Inc. | Golf club |
| US20160058689A1 (en) * | 2014-08-28 | 2016-03-03 | Natura Cosméticos S.A. | Compositions for Cosmetic Formulation Comprising A Mixture Selected From Murumuru Butter, Ucuúba Butter, Brazilian-Nut Oil, Passion Fruit Oil, Cupuassu Butter, Assaí Oil and / or Nhandiroba Oil and / or Esters Therefor, As Well As The Use Of A Mixture for Preparation Of A Cosmetic Product |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023774A1 (pt) * | 2017-07-31 | 2019-02-07 | Natura Cosméticos S.A. | Complexo cosmético para hidratação bioativa, composição cosmética, uso e método |
| US11260021B2 (en) | 2017-07-31 | 2022-03-01 | Natura Cosméticos S.A. | Cosmetic complex for bioactive hydration, cosmetic composition, use and method |
| WO2020206513A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Uso do óleo de fevillea trilobata |
| WO2020206515A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Composição cosmética tópica e usos da mesma |
| WO2020206514A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Complexo cosmético e usos do mesmo |
| EP3954358A4 (en) * | 2019-04-11 | 2023-03-01 | Natura Cosméticos S.A. | COSMETIC COMPLEX AND USES THEREOF |
| EP3954359A4 (en) * | 2019-04-11 | 2023-03-01 | Natura Cosméticos S.A. | TOPICAL COSMETIC COMPOSITION AND USES THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018013860A (es) | 2019-07-18 |
| CL2018003212A1 (es) | 2019-02-15 |
| US20190282492A1 (en) | 2019-09-19 |
| EP3456313A1 (en) | 2019-03-20 |
| EP3456313A4 (en) | 2020-09-23 |
| BR112018073287A2 (pt) | 2019-02-19 |
| AR107263A1 (es) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017193186A1 (pt) | Composições cosméticas para reparação cutânea | |
| CN107405272B (zh) | 包含作为白薇提取物的指标成分的芥子酸或具有其的白薇提取物的皮肤再生用化妆品组合物及伤口治疗用药学组合物 | |
| CN102762189B (zh) | 包含长角豆提取物作为促进水通道蛋白表达活性剂的化妆品和/或药物组合物 | |
| BR112017008726B1 (pt) | Usos de um extrato de fermento e de um exopolissacarídeo, e, composição cosmética | |
| CN110833516B (zh) | 一种具有补水保湿作用的多肽组合物 | |
| CN110302113A (zh) | 一种抗皱去黑眼圈眼霜 | |
| CN105101984B (zh) | 丙氨酸-谷氨酰胺、透明质酸和燕麦提取物的协同组合以及其在用于愈合伤口和修复皮肤损伤的组合物中的用途 | |
| BR112019022610A2 (pt) | utilização cosmética de um extrato de nephelium lappaceum, método de cuidado cosmético, e, extrato | |
| CN108125892A (zh) | 一种海洋生物保湿抗衰老化妆品组合物 | |
| US6193975B1 (en) | Use of potentilla erecta extract in the cosmetic and pharmaceutical field | |
| CN111420023B (zh) | 含i型胶原和透明质酸的复合物及制备和用途 | |
| EP2101879A2 (en) | Cosmetic composition for the treatment and/or prevention of skin stretch marks | |
| WO2017011983A1 (zh) | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 | |
| WO2025091754A1 (zh) | 一种含愈创木提取物的敏感肌祛痘修护组合物及其制备方法 | |
| ES2699239T3 (es) | Utilización cosmética de un extracto de Harungana madagascariensis | |
| CN116672296B (zh) | 具有舒缓修护功效的复方植物提取物、其制备方法及应用 | |
| CN113766922A (zh) | 用于炎症性皮肤病的硫酸葡聚糖 | |
| CN110680776A (zh) | 侧柏的应用 | |
| CN116635042A (zh) | 组合jonzac温泉水与积雪草萃取物的组合物及其修复/愈合作用 | |
| CN114869998A (zh) | 一种修复皮肤屏障的组合物及其制备和应用 | |
| CN107320356A (zh) | 一种胶原紧致精华 | |
| CH706016A2 (de) | Auf Stammzellen der Epidermis und Dermis und auf deren Mikro-Umgebung wirkende kosmetische Zusammensetzung. | |
| WO2018032075A1 (pt) | Composição cosmética antissinais, uso da composição e método para tratamento antissinais | |
| CN118556067A (zh) | 肽以及包含所述肽的药物和美容组合物 | |
| KR101975938B1 (ko) | 금사연 둥지 추출물 및 후코이단을 유효성분으로 포함하는 피부 건조증 개선용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018073287 Country of ref document: BR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16901174 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2016901174 Country of ref document: EP Effective date: 20181212 |
|
| ENP | Entry into the national phase |
Ref document number: 112018073287 Country of ref document: BR Kind code of ref document: A2 Effective date: 20181112 |

